Application of gypenoside TN-1 in preparation of medicine for treating diabetes

Gynostem saponin TN-1 was prepared from Gynostemum by enzymatic transformation method and combined with a carrier to form a pharmaceutical composition for the treatment of diabetes, solving the side effects and drug resistance of existing drugs, and achieving more effective blood sugar control and lipid-lowering effect.

CN118924772APending Publication Date: 2024-11-12SUBTROPICAL CROPS INST OF FUJIAN PROVINCE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411281698.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-13
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing hypoglycemia drugs have major side effects and are prone to drug resistance, and the total saponin of Gynostemma blue is used to treat diabetes and the therapeutic effect needs to be improved.

Method used

The enzymatic conversion method is used to prepare a large amount of gynostemite saponin TN-1 from gynostemite and combined with a pharmaceutically acceptable carrier or excipient to form a variety of dosage forms of pharmaceutical compositions for the treatment of diabetes.

Benefits of technology

Gynostemma saponin TN-1 showed significant inhibitory effects of α-glucosidase and α-amylase, which can effectively reduce the blood sugar level in rats and improve diabetes symptoms. The dosage is only 1/4 of the total saponin of Gynostemma saponin, which shows that Better lowering blood sugar and lipid-lowering effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924772A_ABST
    Figure CN118924772A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of gypenoside TN-1 in preparation of a medicine for treating diabetes. The gypenoside TN-1 is used for treating diabetes mellitus, the dosage of the gypenoside TN-1 is smaller compared with that of gypenoside, and the gypenoside TN-1 has better effects of inhibiting alpha-glucosidase and alpha-amylase, improving the tolerance of diabetic rats to glucose, repairing damaged glucose tolerance, improving the liver state, reducing blood fat and improving the level of GLP-1 in serum.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to an application of gypenoside TN-1 in preparing a drug for treating diabetes. Background Art

[0002] Gynostemma pentaphyllum saponin TN-1, named (20S)-dammarane-24-ene-2α,3β,12β,20-tetraol-20-O-β-D-pyranoglucoside, is a white powder with a molecular formula of C 36 H 62 O9, molecular weight is 638.439, structural formula is:

[0003] Patent CN107904277A discloses a method for preparing gypenoside TN-1, which specifically discloses that gypenoside (Gyp) is a major active ingredient in Gynostemma pentaphyllum, wherein Gyp XLVI is one of the main gypenosides in the aerial part of Gynostemma pentaphyllum in Nanjing, Fujian Province, while the content of another gypenoside, GypTN-1, is very low. Currently, no literature has been found to report in detail the preparation method and biological activity of Gyp TN-1, and it is only found that GypTN-1 can be directly extracted from Gynostemma pentaphyllum, but the yield is very low. See the document "Dammarane-type saponins from Gynostemma pentaphyllum [J]. Phytochemistry, 2011, 72 (11-12): 1453-1459"; Kim et al. extracted 1.085 kg of the aerial part of Gynostemma pentaphyllum by methanol extraction at room temperature for 3 weeks, and then used ODS silica gel column chromatography or MCI column chromatography to finally obtain 18 mg of GypTN-1, with a yield of only 0.00166%. Therefore, GypTN-1 is difficult to directly extract in large quantities from Gynostemma pentaphyllum. This invention adopts the enzymatic conversion method for the first time to prepare Gynostemma pentaphyllum saponin TN-1 in large quantities from Gynostemma pentaphyllum. This patent discloses the preparation method of Gynostemma pentaphyllum saponin TN-1, but does not disclose the use of Gynostemma pentaphyllum saponin TN-1.

[0004] Patent CN107982272A discloses an application of gypenosidone TN-1 in the preparation of anti-liver cancer drugs; the gypenosidone TN-1 can be obtained by enzymatic conversion of gypenosidone total saponins, and is gradually separated and purified, and its preparation method is simple and low in cost. The present invention determines the in vitro anti-liver cancer activity of Gyp TN-1 by measuring the MTT method, colony formation test and AO / EB fluorescence staining, and the results show that gypenosidone TN-1 has a significant inhibitory effect on the growth of human liver cancer cells SMMC7721 and Bel7402. However, it is not found that gypenosidone TN-1 has a hypoglycemic effect.

[0005] As a global chronic disease, the incidence of diabetes is increasing year by year, posing a serious threat to human health. However, existing hypoglycemic drugs are often accompanied by significant side effects and easy to develop drug resistance. Therefore, it is particularly important to develop new, highly effective and low-toxic hypoglycemic drugs.

[0006] Gynostemma pentaphyllum, as a herbaceous vine of the Cucurbitaceae family, contains a variety of active ingredients, among which gynostemma pentaphyllum saponin compounds are particularly prominent and have a wide range of pharmacological effects. These effects include lowering blood lipids, lowering blood sugar, anti-tumor, anti-aging, protecting the liver, and enhancing the body's immune function. In recent years, with the continuous deepening of research on Gynostemma pentaphyllum, people have found that its saponin components have excellent performance in lowering blood sugar, showing great potential for development into new hypoglycemic drugs. The inventor found in research that the use of total gynostemma pentaphyllum saponins as the main ingredient for the treatment of diabetes has the defect of large dosage, and the therapeutic effect needs to be improved. Summary of the invention

[0007] The first purpose of the present invention is to provide the use of gypenoside TN-1 in the preparation of drugs for treating diabetes.

[0008] The dosage of the gypenoside TN-1 is 0.8-16 mg / kg / d.

[0009] Preferably, the dosage of gypenoside TN-1 is 1.6-12.0 mg / kg / d.

[0010] More preferably, the dosage of gypenoside TN-1 is 8.0 mg / kg / d.

[0011] When using rats for animal experiments, the dosage of gamma-macrosaponin TN-1 is 5-100 mg / kg / d, preferably 10-75 mg / kg / d, and more preferably 50 mg / kg / d. According to Xu Shuyun's "Pharmacological Experimental Methodology", the drug dosage is converted to human dosage = rat dosage × 0.2 × 56 / 70. When converted, when used for humans, the dosage of gamma-macrosaponin TN-1 is 0.8-16 mg / kg / d, preferably 1.6-12.0 mg / kg / d, and more preferably 8 mg / kg / d.

[0012] The second object of the present invention is a pharmaceutical composition comprising gypenoside TN-1 and a pharmaceutically acceptable carrier or excipient.

[0013] The pharmaceutical composition can be prepared into one or more dosage forms of tablets, capsules, granules, pellets, suspensions, syrups, enteric-coated preparations, emulsion suspensions and injections.

[0014] The third object of the present invention is to provide the use of the above-mentioned pharmaceutical composition in the preparation of drugs for treating diabetes.

[0015] The present invention has the following beneficial effects:

[0016] (1) The results of the α-glucosidase inhibition assay showed that all gypenosides groups had α-glucosidase inhibition, with the inhibitory effect of gypenosides TN-1 > gypenosides XLVI > gypenosides; and the IC of gypenosides TN-1 on α-glucosidase was 50 The value was close to that of the sample control acarbose, which means that gypenosyl saponin TN-1 is a potential α-glucosidase inhibitor.

[0017] (2) The results of the α-amylase inhibition test showed that all gypenosides groups had α-amylase inhibition, with the effect of gypenosides TN-1>gypenosides XLVI>gypenosides; and the IC value of gypenosides TN-1 on α-amylase was 50 The value was close to that of the sample control acarbose, which means that gypenosyl saponin TN-1 is a potential α-amylase inhibitor.

[0018] (3) The protective effect of gypenosides on type Ⅱ diabetes in rats. The experimental results show that type Ⅱ diabetic rats (model group) have a higher water intake than the normal group, which is consistent with the symptoms of polydipsia in diabetic patients. Each gypenosides group can reduce the daily water intake of rats, indicating that it helps to improve diabetic symptoms; especially gypenosides TN-1, which has a better effect than gypenosides XLVI and total gypenosides. Type Ⅱ diabetic rats (model group) have a higher food intake than the normal group, which is consistent with the symptoms of polydipsia in diabetic patients. Each gypenosides group can reduce the daily food intake of rats, indicating that it helps to improve diabetic symptoms; especially gypenosides TN-1, which has a better effect than gypenosides XLVI and total gypenosides. Within four weeks of administration, the blood sugar of rats in the normal group was generally stable. The blood glucose of rats in the model group was maintained at a high level. The blood glucose of rats in the gypenosides group showed an overall downward trend and was lower than that of rats in the model group, indicating that gypenosides can improve the blood glucose level of rats with T2DM (type Ⅱ diabetes). Among them, gypenosides TN-1 had a better effect than gypenosides XLVI and gypenosides. The blood glucose level on the 28th day was 18.44±2.21mmol / L, which was significantly lower than 28.92±1.46 in the MODEL group (P<0.01). Results of oral glucose tolerance test: The blood glucose of rats in the normal group did not change significantly within 0-120min and remained at a normal level. The blood glucose concentration of rats in the model group and the drug administration group showed a phenomenon of first increasing and then decreasing, reaching the maximum value at 30-60min. At 120min, the FBG of rats in the model group was 30.21±1.45mmol / L. Compared with the model group, the FBG of rats in the gypenosanol TN-1, gypenosanol XLVI and gypenosanol groups were 21.59±1.46mmol / L, 24.53±1.48mmol / L and 25.66±2.05mmol / L, respectively, which were significantly decreased (P<0.05). The results showed that gypenosanols can significantly improve the glucose tolerance of diabetic rats, repair the impaired glucose tolerance, and help improve diabetic symptoms. In particular, gypenosanol TN-1 has a better effect than gypenosanol XLVI and gypenosanols.

[0019] (4) Compared with the model group, the gypenosides group was able to significantly reduce the liver index (P < 0.05), suggesting that it helps to improve the liver status; especially gypenosides TN-1, which had a better effect than gypenosides XLVI and gypenosides.

[0020] (5) The results of blood lipid test showed that the levels of TC and TG in serum of each gypenosides group were significantly reduced compared with the model group (P < 0.05 or P < 0.01), which means that gypenosides can reduce the level of lipid metabolism in the liver of rats with type 2 diabetes and help restore glucose and lipid metabolism to normal levels. Among them, gypenosides TN-1 has a better lipid-lowering effect than gypenosides XLVI and gypenosides.

[0021] (6) The results of the test on glucagon-like peptide 1 (GLP-1) in serum showed that gypenosides TN-1 and XLVI could significantly increase the level of GLP-1 in serum (P < 0.05). GLP-1 has the effect of promoting insulin secretion and inhibiting glucagon secretion, which means that gypenosides TN-1 and XLV can promote the restoration of normal insulin secretion and thus play a role in lowering blood sugar.

[0022] (7) Gynostemma pentaphyllum saponin TN-1 is used to treat diabetes. When used on humans, only 1.6-12.0 mg / kg / d is needed. In animal experiments, the dosage of Gynostemma pentaphyllum saponin TN-1 is only 1 / 4 of the total Gynostemma pentaphyllum saponins, but it shows better effects than total Gynostemma pentaphyllum saponins in inhibiting α-glucosidase and α-amylase, improving the glucose tolerance of diabetic rats, repairing impaired glucose tolerance, improving liver status, lowering blood lipids, and increasing the level of GLP-1 in serum. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is a graph showing the effects of gypenoside TN-1, gypenoside XLVI and total gypenosides on blood glucose in type 2 diabetic rats.

[0024] Figure 2 This graph shows the effects of gypenoside TN-1, gypenoside XLVI and total gypenosides on oral glucose tolerance in type 2 diabetic rats.

[0025] Figure 3 The pictures are of liver tissue pathological examination of type 2 diabetic rats in different groups. A, normal group, B, model group, C, gypenoside TN-1 group, D, gypenoside XLVI group, and E, gypenoside total saponins group. DETAILED DESCRIPTION

[0026] The present application will be further described below in conjunction with the accompanying drawings and specific implementation methods so that those skilled in the art can better understand the present application, but the present invention is not limited thereto.

[0027] Unless otherwise specified, the experimental materials and reagents used in the examples of the present invention are all consumables and reagents that can be obtained from conventional commercial channels.

[0028] The total saponins of Gynostemma pentaphyllum used in the embodiment of the present invention are self-made, and the preparation method is as follows: take the above-ground part of Gynostemma pentaphyllum in Nanjing, Fujian Province as the raw material of Gynostemma pentaphyllum, dry and crush Gynostemma pentaphyllum, heat and extract 70% ethanol at 50°C for 40min, the solid-liquid ratio is 1:10, extract three times, combine the extracts, and concentrate into a fluid extract. The Gynostemma pentaphyllum extract is dispersed and suspended with distilled water, extracted 3 times with water phase: petroleum ether (1:1), degreased and decolorized, and then extracted with water phase: n-butanol (1:1.5) until the n-butanol layer is colorless, combine the n-butanol layers and concentrate under reduced pressure to an extract, freeze-dry, and obtain the total saponins of Gynostemma pentaphyllum. After HPLC analysis, the main component of the total saponins of Gynostemma pentaphyllum is Gynostemma pentaphyllum saponin XLVI, with a content of 6.94%. Gynostemma pentaphyllum saponin TN-1 was not detected.

[0029] Example 1 α-glucosidase inhibition ability determination

[0030] Experimental method: Add 110 μL buffer to a 2 mL centrifuge tube, then add 30 μL 3 mmol / L glutathione and 30 μL α-glucosidase solution (3U / mL) successively, add 30 μL of gradient concentration sample solution, water bath for 15 minutes, add 30 μL 5 mmol / L pNPG and continue water bath for 15 minutes, add 50 μL 2 mmol / L sodium carbonate solution to terminate the reaction, centrifuge at 4000 rpm for 10 minutes, transfer the supernatant to a 96-well plate, and measure at 405 nm. The enzyme solution and sample solution of the blank group were replaced with buffer solution. The enzyme solution of the control group was replaced with buffer solution. The α-glucosidase inhibition ability of samples with different gradient concentrations was calculated according to the following formula: α-glucosidase inhibition rate (%) = [(A1-A2)-(A3-A4)] / (A1-A2)×100%; the final result is expressed as IC 50 Value presentation.

[0031] A1 represents the control group, A2 represents the blank control group, A3 represents gypenosides TN-1, gypenosides XLVI or gypenosides, A4 represents the sample control group, and acarbose is selected as the positive control.

[0032] Experimental results: The experimental results are shown in Table 1. The results show that each gypenosides group has an inhibitory effect on α-glucosidase, and the effect is gypenosides TN-1>gypenosides XLVI>gypenosides; and the IC of gypenosides TN-1 on α-glucosidase is 50 The value is close to that of the sample control acarbose, which means that gypenoside TN-1 is a potential α-glucosidase inhibitor, which may inhibit the hydrolysis of glucosidic bonds, thereby reducing glucose production, and has a potential effect on lowering blood sugar in diabetic patients.

[0033] Table 1 Inhibition of α-glucosidase by different gypenosides samples

[0034] sample <![CDATA[IC 50 (μg / mL)]]> Acarbose 9.25±0.89 Gynostemma pentaphyllum saponin TN-1 45.33±2.55 Gynostemma pentaphyllum saponin XLVI 117.85±3.56 Gynostemma pentaphyllum total saponins 188.61±7.94

[0035] Example 2 α-amylase inhibition ability determination

[0036] Experimental method: Add 150μL α-amylase to a 5mL centrifuge tube. After water bathing for 15 minutes, add 150μL of gradient concentration sample solution and 100μL 1% corn starch solution successively. After water bathing for 15 minutes, add 100μL DNS and boil in water bath for 10 minutes. After cooling, add 2.5mL distilled water. Centrifuge the sample solution at 4000 rpm for 10 minutes. Take the supernatant and measure at 540nm. The blank group enzyme solution and sample solution were replaced with buffer solution. The control group enzyme solution was replaced with buffer solution. The α-amylase inhibition ability of samples with different gradient concentrations was calculated according to the following formula: α-amylase inhibition rate (%) = [(A1-A2)-(A3-A4)] / (A1-A2)×100%; the final result is expressed as IC 50 Value presentation.

[0037] A1 represents the control group, A2 represents the blank control group, A3 represents gypenosides TN-1, gypenosides XLVI or gypenosides, A4 represents the sample control group, and acarbose is selected as the positive control.

[0038] Experimental results: The experimental results are shown in Table 2. The results show that each group of gypenosides has an inhibitory effect on α-amylase, and the effect is gypenosides TN-1>gypenosides XLVI>gypenosides; and the IC of gypenosides TN-1 on α-amylase is 50 The value is close to that of the sample control acarbose, which means that Gynostemma saponin TN-1 is a potential α-amylase inhibitor, which may inhibit the hydrolysis of starch molecules, thereby reducing the production of sugar substances such as glucose and oligosaccharides, and has a potential effect on lowering blood sugar.

[0039] Table 2 Inhibition of α-amylase by different gypenosides samples

[0040] sample <![CDATA[IC 50 (μg / mL)]]> Acarbose 25.47±2.16 Gynostemma pentaphyllum saponin TN-1 66.13±2.19 Gynostemma pentaphyllum saponin XLVI 165.62±7.26 Gynostemma pentaphyllum total saponins 245.21±12.33

[0041] Example 3 Protective effect of gypenosides on type 2 diabetes in rats

[0042] Animal experiment modeling: After 3 days of adaptive feeding, the rats were divided into a normal group (NC) and a model group (MODEL). The normal group was fed with ordinary feed; the model group was fed with a high-fat diet (79% ordinary feed + 1% cholesterol + 10% egg yolk powder + 10% lard). After 4 weeks of feeding, the rats in the model group were intraperitoneally injected with STZ solution (30 mg / Kg (BW), dissolved in 0.1 mmol / L buffer) for 5 consecutive days. On the second day of injection and one week after injection, the blood glucose of the rats in the model group was measured using a blood glucose meter, and rats with fasting blood glucose (FBG) levels >11.1 mmol / L for two consecutive times were considered T2DM rats. Type 2 diabetic rats were randomly divided into four groups (10 rats in each group), including model group (MODEL), gypenosides TN-1 group, gypenosides XLVI group, and gypenosides total saponins group, and were given normal saline, metformin solution (200 mg / kg / d), gypenosides TN-1 (50 mg / kg / d), gypenosides XLVI (50 mg / kg / d), and gypenosides total saponins (200 mg / kg / d), respectively, and rats fed with normal diet (NC) were used as normal group for four weeks. Type 2 diabetic rats were fed with high-fat diet, and NC rats were fed with ordinary diet. Water intake and food intake were monitored every two days, and blood glucose was monitored every 7 days. After the experiment, all rats were fasted for 12 hours, blood was collected from the eyes, and serum was collected by centrifugation at 3000 rpm for 20 minutes at 4℃. The rats were euthanized with ether and the liver was dissected. The serum and liver were labeled and stored in a -80℃ refrigerator for later use.

[0043] 3.1 Water drinking of rats during the experiment

[0044] Experimental results: The experimental results are shown in Table 3. The results show that type 2 diabetic rats (model group) have a higher water intake than the normal group, which is consistent with the symptoms of polydipsia in diabetic patients. Each gypenoside group can reduce the daily water intake of rats, suggesting that it helps to improve diabetic symptoms; especially gypenoside TN-1, which has a better effect than gypenoside XLVI and gypenoside total saponins.

[0045] Table 3 Effects of different gypenosides on drinking water in type Ⅱ diabetic rats

[0046]

[0047] 3.2 Diet of rats during the experiment

[0048] Experimental results: The experimental results are shown in Table 4. The results show that type 2 diabetic rats (model group) have a higher food intake than the normal group, which is consistent with the symptoms of polyphagia in diabetic patients. The gypenoside group can reduce the daily food intake of rats, suggesting that it helps to improve diabetic symptoms; especially gypenoside TN-1, which has a better effect than gypenoside XLVI and gypenoside total saponins.

[0049] Table 4 Effects of different gypenosides on diet of type Ⅱ diabetic rats

[0050]

[0051] 3.3 Blood glucose status of rats during the experiment

[0052] Experimental results: The experimental results are shown in Figure 1 The results showed that within four weeks of administration, the blood sugar level of rats in the normal group was generally stable. The blood sugar level of rats in the model group remained at a high level. The blood sugar level of rats in the gypenosides group showed an overall downward trend and was lower than that of rats in the model group, indicating that gypenosides can improve the blood sugar level of T2DM rats. Among them, gypenosides TN-1 had a better effect than gypenosides XLVI and gypenosides. The blood sugar level on the 28th day was 18.44±2.21mmol / L, which was significantly lower than 28.92±1.46 in the MODEL group (P<0.01).

[0053] 3.4 Oral glucose tolerance test (OGTT)

[0054] Experimental method: After the administration, OGTT was performed on the rats in the normal group, model group, and gypenosin-administered group. The rats were fasted for 12 hours and orally administered with glucose 2g / kg (BW). Blood serum was collected from the tail vein at 0, 30, 60, 90, and 120 minutes after the administration of glucose to measure blood glucose levels.

[0055] Experimental results: The experimental results are shown in Figure 2The results showed that the blood glucose of rats in the normal group did not change significantly within 0-120min, and it remained at a normal level. The blood glucose concentration of rats in the model group and the drug-treated group showed a phenomenon of first increasing and then decreasing, reaching the maximum value at 30-60min. At 120min, the FBG of rats in the model group was 30.21±1.45mmol / L. Compared with the model group, the FBG of rats in the gypenosides TN-1, gypenosides XLVI and gypenosides groups were 21.59±1.46mmol / L, 24.53±1.48mmol / L and 25.66±2.05mmol / L, respectively, which were significantly decreased (P<0.05). The results showed that gypenosides can significantly improve the glucose tolerance of diabetic rats, repair impaired glucose tolerance, and help improve diabetic symptoms. In particular, gypenosides TN-1 has a better effect than gypenosides XLVI and gypenosides.

[0056] 3.5 Detection of liver index

[0057] Experimental method: The surface water of the rat liver obtained by dissection was dried and weighed using an electronic balance. The formula: liver index (%) = liver weight / body weight × 100% was used to obtain the rat liver-body ratio.

[0058] Experimental results: The experimental results are shown in Table 5. The results show that the gypenosides group can significantly reduce the liver index compared with the model group (P < 0.05), suggesting that it helps to improve the liver state; especially gypenosides TN-1, which has a better effect than gypenosides XLVI and gypenosides.

[0059] Table 5 Effects of different gypenosides on liver indexes in type Ⅱ diabetic rats

[0060] Grouping Liver index% Normal group 4.35±0.26 Model Group <![CDATA[7.45±0.41 ** ]]> Gynostemma pentaphyllum saponin TN-1 <![CDATA[5.28±0.37 # <!-- 6 -->]]> Gynostemma pentaphyllum saponin XLVI <![CDATA[5.83±0.48 # ]]> Gynostemma pentaphyllum total saponins <![CDATA[6.07±0.68 # ]]>

[0061] ** Compared with the normal group, P < 0.01; # Compared with the model group, P < 0.05.

[0062] 3.6 Blood lipid testing

[0063] Experimental method: Determine the total cholesterol TC and triglyceride TG levels in serum according to the determination method of the kit.

[0064] Experimental results: The experimental results are shown in Table 6. The results show that each gypenosides group can significantly reduce the levels of TC and TG in serum compared with the model group (P < 0.05 or P < 0.01), which means that gypenosides can reduce the level of lipid metabolism in the liver of type 2 diabetic rats and help restore the level of glucose and lipid metabolism. Among them, gypenosides TN-1 has a better lipid-lowering effect than gypenosides XLVI and gypenosides.

[0065] Table 6 Effects of different gypenosides on blood lipid levels in type Ⅱ diabetic rats

[0066] Grouping TC(mmol / L) TG (mmol / L) Normal group 2.48±0.18 1.78±0.15 Model Group <![CDATA[5.45±0.36 ** ]]> <![CDATA[3.57±0.20 ** ]]> Gynostemma pentaphyllum saponin TN-1 <![CDATA[3.38±0.17 ## ]]> <![CDATA[2.38±0.25 # ]]> Gynostemma pentaphyllum saponin XLVI <![CDATA[3.83±0.38 # ]]> <![CDATA[2.83±0.11 # ]]> Gynostemma pentaphyllum total saponins <![CDATA[4.07±0.22 # ]]> 3.04±0.16

[0067] ** Compared with the normal group, P < 0.01; #,## Compared with the model group, P < 0.05, 0.01.

[0068] 3.7 Detection of glucagon-like peptide-1 (GLP-1) in serum

[0069] Experimental method: Determine the GLP-1 content in serum according to the determination method of the kit.

[0070] Experimental results: The experimental results are shown in Table 7. The results show that compared with the model group, gypenosides TN-1 and XLVI can significantly increase the level of GLP-1 in serum (P < 0.05). GLP-1 has the effect of promoting insulin secretion and inhibiting glucagon secretion, which means that gypenosides TN-1 and XLV can promote the restoration of normal insulin secretion, thereby playing a role in lowering blood sugar.

[0071] Table 7 Effects of different gypenosides on GLP-1 in type Ⅱ diabetic rats

[0072] Grouping GLP-1 (mmol / L) Normal group 2.35±0.31 Model Group <![CDATA[1.30±0.17 * ]]> Gynostemma pentaphyllum saponin TN-1 <![CDATA[2.08±0.27 # ]]> Gynostemma pentaphyllum saponin XLVI <![CDATA[1.80±0.28 # ]]> Gynostemma pentaphyllum total saponins 1.57±0.16

[0073] * Compared with the normal group, P < 0.05; #,## Compared with the model group, P < 0.05.

[0074] 3.8 H&E staining

[0075] Experimental method: The collected rat livers were fixed in 4% paraformaldehyde for 24 hours, dehydrated with gradient alcohol and then embedded in paraffin. The slices were sliced ​​with a thickness of about 4-8 μm using a pathological slicer, dewaxed with xylene, stained with HE staining solution after gradient alcohol to water, and observed and photographed under a microscope.

[0076] Experimental results: The experimental results are shown in Figure 3The normal group rats had clear liver lobule structure and neatly arranged liver cords. The model group rats had unclear liver lobule structure and twisted liver cords; a large number of hepatocytes had vacuolar degeneration, blurred cell edges and abnormal morphology, reflecting the obvious pathological changes in liver tissue after type 2 diabetes modeling; the Gynostemma pentaphyllum saponin groups significantly restored this pathological damage to liver tissue, especially Gynostemma pentaphyllum saponin TN-1 had the best effect. From the pathological pictures, the Gynostemma pentaphyllum saponin TN-1 group rats had clear liver lobule structure, neatly arranged liver cords, mild vacuolar degeneration of liver cells, and tiny vacuoles in the cytoplasm; the degree of vacuolar degeneration in Gynostemma pentaphyllum saponin XLVI and Gynostemma pentaphyllum total saponin groups was higher than that in Gynostemma pentaphyllum saponin TN-1.

Claims

1. Application of Gynostemma pentaphyllum saponin TN-1 in the preparation of drugs for the treatment of diabetes.

2. The use according to claim 1, characterized in that: The dosage of the gypenoside TN-1 is 0.8-16 mg / kg / d.

3. The use according to claim 1, characterized in that: The dosage of the gypenoside TN-1 is 1.6-12.0 mg / kg / d.

4. The use according to claim 3, characterized in that: The dosage of the gypenoside TN-1 is 8 mg / kg / d.

5. A pharmaceutical composition, characterized in that Contains the gypenoside TN-1 according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier or excipient.

6. Use of the pharmaceutical composition according to claim 5 in the preparation of a drug for treating diabetes.